The Growing GLP-1 Therapy Market
Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.
You may also be interested in...
Novo Nordisk at its Q1 update lifted full-year guidance and voiced confidence it can double sales of innovative treatments for obesity by 2025.
Novo Nordisk’s semaglutide, a GLP-1 agonist marketed in an injected formulation as Ozempic, and an oral tablet form as Rybelsus, is a success story with the potential for an epic third act. First approved as a treatment for type 2 diabetes, semaglutide is under FDA review as a treatment for obesity, with additional clinical programs in NASH and Alzheimer’s disease.
In Vivo’s 2021 Rising Leader Alvine Tremoulet favored backroads over the corporate highway en route to her current position as global diversity, equity and inclusion lead at Pfizer. Tremoulet’s background in communications, and a strong network of female leaders, helped her to successfully influence internal and external stakeholders on issues still considered taboo in many parts of the world.